SCHEMBL1035542

SCHEMBL1035542

O=C(Nc1ccccn1)Nc1cccc2ccc(-c3cccc(OC(F)(F)F)c3)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.52
FGFR1 P11362 2/20 0.52
KDR P35968 2/20 0.52
SIRT2 Q8IXJ6 1/20 0.44
SLC40A1 Q9NP59 1/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GRM5 P41594 1/20 0.42
P2RY1 P47900 2/20 0.42
NTRK1 P04629 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR2 P34972 1/20 0.41
NTRK3 Q16288 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036232 0.86 SIRT2 (0.50) EGFRFGFR1KDRSIRT2NPC1
SCHEMBL1029917 0.83 EGFR (0.54) EGFRFGFR1KDRSIRT2SLC40A1
SCHEMBL1035290 0.82 NPC1 (0.55) EGFRFGFR1KDRSIRT2NPC1
SCHEMBL1029916 0.81 HDAC1 (0.52) KDRSIRT2
SCHEMBL1035313 0.79 IRAK4 (0.47) NPC1RAB9AMAPTGAA
SCHEMBL1029914 0.79 NPC1 (0.52) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1030376 0.78 IRAK4 (0.47) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1034300 0.78 GRM5 (0.44) KDRSLC40A1NPC1RAB9AGRM5
SCHEMBL1076614 0.78 HDAC1 (0.51) EGFRNPC1RAB9AMEN1KMT2A
SCHEMBL1035541 0.77 KAT6A (0.48) KDRSIRT2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 EGFR 4745/4885FGFR1 2345/4885KDR 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.